Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.35 USD | -0.56% | +7.21% | +25.29% |
Mar. 20 | Bristol Myers Squibb Gets EU OK for Cancer Treatment | DJ |
Mar. 20 | Engine Capital Nominates Candidates to the Board of 2seventy bio | CI |
Evolution of the average Target Price on 2seventy bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering 2seventy bio, Inc.
TD Cowen | |
Leerink Partners | |
Wedbush | |
Citigroup | |
Goldman Sachs | |
Guggenheim | |
Morgan Stanley | |
SVB Securities LLC | |
Canaccord Genuity | |
SVB Leerink | |
Cowen |
EPS Revisions
- Stock
- Equities
- Stock 2seventy bio, Inc. - Nasdaq
- Consensus 2seventy bio, Inc.